# VELCADE® (bortezomib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bortezomib

> The FDA approved VELCADE® (bortezomib), sponsored by DR REDDYS LABORATORIES LTD (RDY), on May 2, 2022.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VELCADE® (bortezomib) |
| Codes |  |
| Sponsor | DR REDDYS LABORATORIES LTD (RDY) https://sec-api.dev/companies/rdy/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | accelerated |

## Timeline

### December 17, 2014: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "should specify We have completed our review of NDA 206927/Original 1 eM and have determined that we cannot approve these application(s) in their present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22206927_2019_Orig1s000OtherActionLtrs.pdf%22

### May 4, 2016: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of NDA 206927/Original 1 OM as amended, and have determined that we cannot approve these applications in their present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22206927_2019_Orig1s000OtherActionLtrs.pdf%22

### November 3, 2017: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22209191_2018_Orig1s000OtherActionLtrs.pdf%22

### February 22, 2018: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22209191_2018_Orig1s000OtherActionLtrs.pdf%22

### October 4, 2019: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA206927 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20191004, review_priority STANDARD; sponsor_name DR REDDYS; product BORTEZOMIB (BORTEZOMIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206927%22

### May 2, 2022: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209191 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20220502, review_priority STANDARD; sponsor_name HOSPIRA; product BORTEZOMIB (BORTEZOMIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209191%22

### December 9, 2022: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA209191 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20221209, review_priority STANDARD; sponsor_name HOSPIRA; product BORTEZOMIB (BORTEZOMIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209191%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bortezomib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VELCADE® (bortezomib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bortezomib

```bibtex
@misc{secapidev_pdufa_bortezomib_20261116,
  title        = {VELCADE® (bortezomib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bortezomib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bortezomib_20261116","title":"VELCADE® (bortezomib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bortezomib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
